Abstract 639P
Background
Maintenance therapy with fluoropyrimidines (such as capecitabine [Cap]) following induction therapy is wildly recommended to unresectable mCRC patients. Fruquintinib (Fru) is a highly selective inhibitor of VEGFR1/2/3 with conspicuous safety and efficacy in mCRC. We sought to evaluate and compare the therapeutic potential of Fru plus Cap (FC) versus Cap as maintenance therapy for mCRC.
Methods
Eligibility criteria included: histologically confirmed mCRC (stage IV), age ≥ 18 years, ECOG PS 0-2, achieved disease control (including CR/PR and SD) after ≥ 6 cycles of first-line standard chemotherapy and still unresectable. In safety lead-in phase (SP), patients (pts) were orally administered with Fru (4 mg, QD, d1-21, Q4W) plus Cap (850 mg/m2, BID, d1-7 and d15-21, Q4W). In expansion phase, pts were randomized in a 1:1 ratio between FC (Arm A) and Cap (Arm B) only. The primary objectives were to characterize safety, confirm the recommended phase 2 dose (RP2D; in phase SP), and evaluate the efficacy (in phase EP).
Results
As of April 24, 2023, 22 pts were enrolled (SP: n = 6; EP: Arm A/B n/n = 7/7). In phase SP, 1 pt experienced DLT of grade 3 oral mucositis. The treatment emergent AEs (TEAEs, Grade ≥3) were hypertension (1/6), oral mucositis (1/6), voice alteration (1/6), small intestinal obstruction (1/6) and blood bilirubin increased (1/6). After full consideration about patient’s tolerance and safety, the RP2D of Fru was adjusted from 4mg to 3mg through charrette. In Arm A, the most common TEAEs (Grade ≥3) were merely hypertension and leukopenia. Intriguingly, these results provided further evidence that reducing RP2D from 4 mg to 3mg can ensure the safety and tolerance. In 6 evaluable pts of phase SP, the DCR was 100% while the mPFS was immaturity, but 3 pts showed the PFS of ≥ 6 months (7.5, 8.6, 8.9 mon, respectively).
Conclusions
The combination of fruquintinib plus capecitabine demonstrated an acceptable tolerability profile. Preliminary antitumor activity was observed in pts with mCRC that revealed promising efficacy and safety as a first-line maintenance therapy. Dose expansion is ongoing at the RP2D in dedicated mCRC.
Clinical trial identification
NCT05451719.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11